Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ret finger protein-like 4A-like protein 1 (RFPL4AL1) is a predicted E3 ubiquitin-protein ligase encoded by the human *RFPL4AL1* gene on chromosome 19. It is predicted to participate in ubiquitin-mediated protein degradation, the regulation of transcription, positive regulation of canonical NF-kappaB signal transduction, autophagy, regulation of gene expression, and may play a role in the innate immune response. Its predicted cellular locations are the cytosol and nucleoplasm. There is no evidence from the biomedical literature or drug databases that RFPL4AL1 is an established therapeutic target, nor that it is involved in common therapeutic pathways. The gene is associated with "Photoparoxysmal Response 1," although a functional or mechanistic connection has not been rigorously established. No drugs, clinical biomarkers, or validated mechanisms of action have been identified for this protein to date[1][2][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ret finger protein-like 4A-like protein 1 (RFPL4AL1).